secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2024-09-11T23:59:59+00:00
Accession:  0000950170-24-105344
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara sets Sept 20 vote on TuHURA merger; REM-001 enrolled 4 of 10 patients; warns of bankruptcy without deal
--------------------------------------------------------------------------------

- Special Meeting on Sept 20, 2024 to vote on TuHURA merger; existing holders get 5.45% of combined co. plus CVRs.
- REM-001 CMBC study: 4 of 10 target patients enrolled as of Sept 10, 2024; no safety issues; Phase 3 dose assessment ongoing.
- Without the merger, Kintara states it likely lacks adequate resources to continue operations and may seek bankruptcy protection.
- Majority of REM-001 costs covered by $2.0M SBIR grant from NIH; potential to offer much needed treatment for CMBC.
- CVRs allow additional shares if ≥10 patients enrolled and complete 8-week follow-up by Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024105344/0000950170-24-105344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024105344/ktra-20240911.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-105344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer